EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of a protein kinase C epsilon inhibitor on insulin signalling in lipid-treated HepG2 hepatocytes and glucose tolerance in fat-fed mice

Miguel L Agoncillo, Zhongmin Gao, Harmannus C De Kraker, Stanton F McHardy, Robert O Messing, Lewin Small, Carsten Schmitz-Peiffer

European Journal of Pharmacology · 2025

DOI: 10.1016/j.ejphar.2025.177465 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Pharmacology, 2025. Verfasst von Miguel L Agoncillo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. Electronic address: m.agoncillo@unswalumni.com. Hauptthemen laut MEDLINE: Protein Kinase C-epsilon, Insulin, Signal Transduction, Hepatocytes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Perpetual Ltd, Hillcrest Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Protein kinase C epsilon (PKCε) plays a causative role in the development of glucose intolerance, and is a potential target for the treatment of type 2 diabetes. Here, we examined the effects of the PKCε inhibitor CIDD-0150612 (CP612) on insulin action in palmitate-treated HepG2 hepatocytes in vitro and on glucose homeostasis in fat-fed mice in vivo. METHODS: HepG2 cells were treated with palmitate and CP612 and stimulated with insulin. Insulin signalling was examined by immunoblotting and glucose incorporation into glycogen was measured using glucose tracer. Mice were fed a high-fat diet and treated with CP612 prior to glucose tolerance tests and tissue harvest. Proteomic analysis of liver was carried out by mass spectrometry. RESULTS: CP612 promoted Akt phosphorylation in a highly insulin-dependent manner and reversed the inhibition of insulin-stimulated Akt phosphorylation and glucose incorporation into glycogen by palmitate. Fat-fed mice treated with CP612 had reduced fat mass, but not lean mass, compared with vehicle-treated littermates. Mice treated acutely with CP612 exhibited elevated fasting blood glucose. However, mice studied 24h after the last dose had lower fasting glucose and improved glucose tolerance with a lower insulin excursion. Proteomic analysis of liver from CP612-treated fat-fed mice indicated a reduction in gluconeogenic gene expression and decreased phosphorylation of the transcription factor Foxk1. CONCLUSIONS: The PKCε inhibitor CP612 had beneficial effects on insulin action in hepatocytes and on fat mass and glucose homeostasis in mice. Because certain effects were not previously observed in genetically PKCε-deficient mice, off-target effects may be partly responsible.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase C-epsilonInsulinSignal TransductionHepatocytesProtein Kinase InhibitorsAnimalsHep G2 CellsHumansMiceMaleDiet, High-FatProto-Oncogene Proteins c-aktGlucose Tolerance TestBlood GlucoseMice, Inbred C57BLLiverGlucosePhosphorylation

Stichwörter der Autor:innen

Coiled-coil containing protein kinaseGlucose toleranceInsulin resistanceInsulin signallingObesityProtein kinase CRho-associatedType 2 diabetes

Substanzen

Protein Kinase C-epsilonInsulinProtein Kinase InhibitorsProto-Oncogene Proteins c-aktBlood GlucoseGlucose

Autor:innen und Institutionen

  • Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. Electronic address: m.agoncillo@unswalumni.com.
  • Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia. Electronic address: john.gaozhongmin@gmail.com.
  • Department of Chemistry, Center for Innovative Drug Discovery, University of Texas San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA. Electronic address: hc.dekraker@gmail.com.
  • Department of Chemistry, Center for Innovative Drug Discovery, University of Texas San Antonio, One UTSA Circle, San Antonio, TX, 78249, USA. Electronic address: Stanton.McHardy@utsa.edu.
  • Department of Neuroscience, University of Texas at Austin, E 24th Street, Austin, TX, 78712, USA. Electronic address: romessing@austin.utexas.edu.
  • Charles Perkins Centre, School of Life and Environmental Sciences, University of Sydney, NSW, 2006, Australia. Electronic address: lewin.small@sydney.edu.au.

Förderung

  • Perpetual Ltd
  • Hillcrest Foundation

Zitieren

APA

Agoncillo, M. L., Gao, Z., De Kraker, H. C., McHardy, S. F., Messing, R. O., Small, L., & Schmitz-Peiffer, C. (2025). Effects of a protein kinase C epsilon inhibitor on insulin signalling in lipid-treated HepG2 hepatocytes and glucose tolerance in fat-fed mice. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.177465

Vancouver

Agoncillo ML, Gao Z, De Kraker HC, McHardy SF, Messing RO, Small L, et al. Effects of a protein kinase C epsilon inhibitor on insulin signalling in lipid-treated HepG2 hepatocytes and glucose tolerance in fat-fed mice. European Journal of Pharmacology. 2025. doi:10.1016/j.ejphar.2025.177465

BibTeX
@article{Agoncillo2025,
  author = {Agoncillo, Miguel L and Gao, Zhongmin and De Kraker, Harmannus C and McHardy, Stanton F and Messing, Robert O and Small, Lewin and Schmitz-Peiffer, Carsten},
  title = {Effects of a protein kinase C epsilon inhibitor on insulin signalling in lipid-treated HepG2 hepatocytes and glucose tolerance in fat-fed mice},
  journal = {European Journal of Pharmacology},
  year = {2025},
  doi = {10.1016/j.ejphar.2025.177465}
}
Kostenlos starten →